InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 28 September 2022

MoST Addendum 14 (substudy 32): This phase II study is evaluating the effect of a targeted therapy (alectinib) in people with newly diagnosed metastatic non-squamous small cell lung cancer (NSCLC) or people with advanced solid cancers with ALK gene alterationsA Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling

Clinical summary

Summary

This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program (ACTRN12616000908437). Eligible participants will receive continuous alectinib (600mg oral capsules) twice a day until disease progression, participant withdrawal or unacceptable toxicity.

Conditions

This trial is treating patients with newly diagnosed metastatic non-squamous non-small cell lung cancer, and advanced or metastatic solid cancers with ALK gene alteration.

Cancer

Advanced Cancers Advanced

Age

People18+

Phase

II

Trial Acronym

MoST Addendum 14 (substudy 32)

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

  • CTC 0141 – ADDENDUM 14; U1111-1263-7887

Commercial Sponsor

University of Sydney, OMICO - Outsmarting Cancer Together

Scientific Title

A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling

Eligibility

Inclusion

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

Submitting ... Please wait

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.